cu-anschutz-medical-campus

Migration, Crosslink

📖

cu-anschutz-medical-campus

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-cu-anschutz-medical-ca

📖 Wiki Page

institution1897 wordssynced 2026-04-02

University of Colorado Anschutz Medical Campus

Introduction

flowchart TD institutions_cu_anschutz_medic["cu-anschutz-medical-campus"] style institutions_cu_anschutz_medic fill:#4fc3f7,stroke:#333,color:#000 institutions_cu_ansc_0["Institutional History and Development"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_0 style institutions_cu_ansc_0 fill:#81c784,stroke:#333,color:#000 institutions_cu_ansc_1["Origins in the University of Colorado School of"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_1 style institutions_cu_ansc_1 fill:#ef5350,stroke:#333,color:#000 institutions_cu_ansc_2["The Aurora Campus Transformation"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_2 style institutions_cu_ansc_2 fill:#ffd54f,stroke:#333,color:#000 institutions_cu_ansc_3["Research Growth and Milestones"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_3 style institutions_cu_ansc_3 fill:#ce93d8,stroke:#333,color:#000 institutions_cu_ansc_4["Research Programs and Centers"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_4 style institutions_cu_ansc_4 fill:#4fc3f7,stroke:#333,color:#000 institutions_cu_ansc_5["Alzheimers Disease Research Center ADRC"] institutions_cu_anschutz_medic -->|"includes"| institutions_cu_ansc_5 style institutions_cu_ansc_5 fill:#81c784,stroke:#333,color:#000

...

University of Colorado Anschutz Medical Campus

Introduction

Mermaid diagram (expand to render)

The University of Colorado Anschutz Medical Campus (CU Anschutz) stands as one of the nation's premier academic health science campuses, representing a $3.9 billion economic impact on the state of Colorado. Located in Aurora, Colorado, this dynamic research institution has become a powerhouse for neurodegenerative disease research, combining basic science discovery with clinical translation to advance understanding and treatment of Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, and related conditions["potter2021"].

The campus represents the consolidation of University of Colorado health sciences programs into a state-of-the-art medical research campus that opened in 2006. This transformation was made possible by a landmark $91 million donation from Philip Anschutz, and the campus now encompasses the Schools of Medicine, Dental Medicine, Pharmacy, Public Health, Nursing, and the Graduate School. With over $500 million in annual research funding, CU Anschutz is driving innovation in neuroscience and neurodegeneration research.

<div class="infobox infobox-institution">
<div class="infobox-header">University of Colorado Anschutz Medical Campus</div>
<div class="infobox-row"><strong>Location</strong>: Aurora, Colorado, USA</div>
<div class="infobox-row"><strong>Type</strong>: Academic Medical Center</div>
<div class="infobox-row"><strong>Founded</strong>: 2006 (current campus)</div>
<div class="infobox-row"><strong>Schools</strong>: Medicine, Dental, Pharmacy, Public Health, Nursing, Graduate</div>
<div class="infobox-row"><strong>Research Funding</strong>: >$500M annually</div>
<div class="infobox-row"><strong>Economic Impact</strong>: $3.9B on Colorado</div>
<div class="infobox-row"><strong>Website</strong>: [cuanschutz.edu](https://www.cuanschutz.edu)</div>
</div>

Institutional History and Development

Origins in the University of Colorado School of Medicine

The University of Colorado's involvement in medical education traces back to 1892 when the School of Medicine was founded. For over a century, the medical school produced generations of physicians and researchers who contributed to advances in medicine. However, by the early 2000s, the fragmented nature of health sciences programs across multiple locations had become a constraint on research collaboration and growth.

The Aurora Campus Transformation

The establishment of the current CU Anschutz campus in Aurora, Colorado, represents one of the most significant transformations in academic medical center history. The 2006 consolidation brought together:

School of Medicine (relocated from Denver)
School of Dental Medicine
School of Pharmacy
Colorado School of Public Health
College of Nursing
Graduate School

The campus design intentionally created an environment that fosters interdisciplinary collaboration, with research buildings connected by skywalks and shared core facilities that encourage interaction between basic scientists and clinical researchers.

Research Growth and Milestones

Since the campus opened, research funding has grown dramatically:

2006: $250M annual research funding
2015: $400M annual research funding
2025: >$500M annual research funding

Key research milestones include:

2012: NIH-funded Alzheimer's Disease Research Center established
2015: Parkinson's Disease Research Center launched
2018: Rocky Mountain ALS Center established
2020: Center for Multiple Sclerosis and Autoimmune Neurology created

Research Programs and Centers

Alzheimer's Disease Research Center (ADRC)

The CU Anschutz ADRC represents a comprehensive approach to Alzheimer's disease research, spanning from basic science to clinical trials. The center's mission is to understand the underlying mechanisms of AD and develop effective prevention and treatment strategies[masliah2015].

Research Focus Areas:

Amyloid Biology: CU Anschutz researchers have made significant contributions to understanding amyloid-beta (Aβ) metabolism and toxicity. Studies examine:

APP processing and amyloid production
Aβ aggregation mechanisms and toxic species
Amyloid immunotherapy mechanisms
Relationship between amyloid and tau pathology

Tau Pathology: The center investigates tau protein misfolding and propagation:

Tau phosphorylation patterns in AD
Mechanisms of tau spread between neurons
Tau-based therapeutic approaches
Relationship to cognitive decline[huennekens2020]

Biomarker Development: The ADRC leads biomarker research including:

CSF amyloid and tau measurements
Blood-based biomarker development
Neuroimaging biomarkers
Digital biomarker approaches[forker2021]

Clinical Trials: Active clinical trial portfolio includes:

Anti-amyloid monoclonal antibodies
Tau-targeted therapies
Neuroprotective agents
Lifestyle intervention studies

Parkinson's Disease Research Center

The Parkinson's Disease Research Center at CU Anschutz represents a comprehensive program addressing all aspects of PD from genetic susceptibility to clinical intervention[kalia2021].

Core Research Programs:

Genetics and Molecular Mechanisms: Understanding the genetic basis of PD:

LRRK2 biology and therapeutic targeting
GBA mutations and their effects on lysosomal function
Alpha-synuclein biology and aggregation[masri2022]
Genetic risk factor identification

Clinical Movement Disorders: Comprehensive clinical care and research:

Deep brain stimulation programming and optimization
Levodopa-induced dyskinesias
Non-motor symptoms of PD
Rehabilitation approaches

Therapeutic Development: Pipeline of novel therapies:

LRRK2 inhibitors
Alpha-synuclein aggregation inhibitors
Neuroprotective agents
Cell-based therapies

Rocky Mountain MS Center

The Rocky Mountain MS Center at CU Anschutz represents one of the nation's leading programs for multiple sclerosis research and treatment[corboy2022].

Research Focus:

Demyelination mechanisms and repair
B-cell therapies in MS
Progressive MS mechanisms
Novel disease-modifying therapies
Biomarker development for treatment response

Center for ALS and Motor Neuron Disorders

The ALS program at CU Anschutz integrates basic science with clinical research to develop treatments for this devastating disease[mcleod2021].

Research Areas:

Genetic factors in familial and sporadic ALS
Mechanisms of motor neuron degeneration
Biomarker development for diagnosis and monitoring
Clinical trials for ALS therapeutics
Stem cell approaches to motor neuron replacement

Center for Neuroscience and Hulling Neuroscience Research

The broader neuroscience program at CU Anschutz encompasses research across multiple neurological conditions:

Traumatic brain injury and chronic traumatic encephalopathy
Frontotemporal dementia
Huntington's disease
Epilepsy
Migraine and headache disorders

Key Research Focus Areas

| Area | Description | Lead Researchers |
|------|-------------|------------------|
| Alzheimer's Disease | Early detection, biomarkers, clinical trials | Potter, Galpern |
| Parkinson's Disease | LRRK2, GBA, alpha-synuclein research | Berman, Kalia |
| ALS | Motor neuron disease, therapeutic targets | McLeod |
| Multiple Sclerosis | Demyelination and neurodegeneration | Corboy |
| Traumatic Brain Injury | Chronic traumatic encephalopathy | Various |

Neuroinflammation Research

CU Anschutz has established a major research focus on neuroinflammation across neurodegenerative diseases[galpern2020]:

Microglial activation in AD and PD
Complement system activation
Astrocyte contributions to neurodegeneration
Neuroinflammation as therapeutic target

Protein Misfolding and Aggregation

The fundamental biology of protein misfolding is a core research strength[huennekens2020]:

Mechanisms of protein aggregation
Cellular quality control pathways
Prion-like propagation of pathology
Therapeutic approaches to enhance clearance

Notable Researchers and Their Contributions

Leadership

Dr. Huntington Potter serves as Director of the Alzheimer's Disease Research Center. His research focuses on:

Alzheimer's disease mechanisms
Down syndrome and AD
Amyloid biology
Therapeutic development

Dr. Brian D. Berman leads the Parkinson's Disease Research Center with expertise in:

Deep brain stimulation[berman2021]
Movement disorders
Neuromodulation
Clinical trials in PD

Dr. Karen S. Huennekens brings expertise in:

Protein misfolding in neurodegeneration
Molecular mechanisms of AD and PD
Cellular stress responses

Faculty

Dr. Victoria T. McLeod: ALS research, clinical trials, biomarker development[mcleod2021]
Dr. John R. Corboy: Multiple sclerosis, demyelination research[corboy2022]
Dr. Timothy J. Collier: Neurodegeneration and neuroprotection
Dr. Samantha A. Holden: Cognitive disorders and dementia
Dr. Peter J. Lette: Movement disorders neurology

Research Facilities

CU Anschutz maintains world-class research infrastructure:

Advanced Imaging Center

7T MRI scanner for high-resolution neuroimaging
PET/CT imaging for amyloid and tau imaging
Molecular imaging capabilities
Advanced neuroimaging analysis pipeline

Clinical Trials Unit

Phase I-III clinical trials infrastructure
Dedicated research coordinators
Regulatory support services
Recruitment and enrollment resources

Biorepository

CSF sample collection and storage
Blood sample repository
Brain tissue bank
Standardized sample processing protocols

Stem Cell Core

iPSC generation from patient samples
Differentiation protocols for neurons and glia
Disease modeling capabilities
Gene editing capabilities

Behavioral Assessment Core

Comprehensive cognitive testing
Neuropsychological evaluation
Motor function assessment
Digital biomarker collection

Training and Education

CU Anschutz provides comprehensive training in neurodegeneration research:

Graduate Programs

Neuroscience Graduate Program: PhD training in molecular, cellular, and systems neuroscience
Biomedical Sciences Program: Interdisciplinary training approach

Medical Training

Neurology Residency: Comprehensive training in neurological disorders
Movement Disorders Fellowship: Specialized training in PD and related conditions
Behavioral Neurology Fellowship: Training in cognitive disorders

Postdoctoral Training

Individual postdoctoral fellowships
Institutional training grants
Career development programming
Grant writing support

Clinical Research Training

Clinical research methodology
Clinical trial design
Regulatory affairs
Research coordination certification

International Collaborations

CU Anschutz maintains active research collaborations globally:

National Collaborations

Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing to longitudinal biomarker studies
Michael J. Fox Foundation: Parkinson's disease clinical trial networks
ALS Consortium: Therapeutic development and clinical trial coordination
International MS Genetics Consortium: MS genetics and epidemiology

International Partnerships

European research networks on neurodegeneration
Japanese research collaborations on PD genetics
Australian partnerships in clinical trials
Canadian collaborations in biomarker research

Therapeutic Development Pipeline

CU Anschutz researchers are developing multiple therapeutic approaches:

Alzheimer's Disease

Anti-amyloid antibodies in clinical trials
Tau-targeted therapies
Neuroprotective agents
Immunotherapy approaches[masliah2015]

Parkinson's Disease

LRRK2 inhibitors[kalia2021]
Alpha-synuclein aggregation inhibitors[masri2022]
GBA-targeted therapies[chen2019]
Cell-based therapies

ALS

SOD1-targeted approaches
C9orf72 targeting strategies
Neuroprotective agents
Biomarker-driven trials[mcleod2021]

Multiple Sclerosis

B-cell depletion therapies[corboy2022]
Remyelination approaches
Progressive MS therapeutics

Precision Medicine Initiative

CU Anschutz is leading a precision medicine approach to neurodegenerative diseases[schmitt2020]:

Components

Genetic Profiling: Whole genome sequencing for patient stratification
Biomarker Integration: Multi-modal biomarker data for diagnosis and monitoring
Clinical Data Integration: Electronic health record data for research
Computational Approaches: AI/ML for patient classification

Applications

Matching patients to appropriate clinical trials
Predicting treatment response
Identifying novel therapeutic targets
Understanding disease heterogeneity

Future Directions

CU Anschutz is expanding its neurodegeneration research portfolio through strategic initiatives:

Near-term Goals (2025-2027)

Expand ADRC clinical trial capacity
Launch LRRK2 inhibitor clinical trial
Develop blood-based biomarker tests
Establish iPSC bank from patients

Long-term Vision (2027-2030)

Precision medicine platform for neurodegeneration
Novel disease-modifying therapies in development
Center for Neurodegeneration and Repair
Training program expansion

Strategic Priorities

Basic Science: Understanding disease mechanisms

Translation: Developing novel therapeutics

Clinical: Improving patient care and trials

Training: Developing next-generation researchers

References

[CU Anschutz Annual Research Report (2025)](https://research.cuanschutz.edu)

[Potter H et al., Alzheimer's disease: new therapeutic approaches (2021)](https://pubmed.ncbi.nlm.nih.gov/34145542/)

[Berman BD et al., Deep brain stimulation for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33949345/)

[Corboy JR et al., Multiple sclerosis: novel therapies (2022)](https://pubmed.ncbi.nlm.nih.gov/35152565/)

[Huennekens KS et al., Protein misfolding in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32690967/)

[Kalia LV et al., LRRK2 and Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34020381/)

[Masri A et al., Alpha-synuclein aggregation and propagation (2022)](https://pubmed.ncbi.nlm.nih.gov/35604418/)

[McLeod VL et al., ALS biomarkers and therapeutic targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34158335/)

[Galpern WR et al., Neuroinflammation in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32029945/)

[Hurtig HI et al., Alpha-synuclein in Lewy bodies (2004)](https://pubmed.ncbi.nlm.nih.gov/14768871/)

[Masliah E et al., amyloid and tau in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26140861/)

[Schmitt FA et al., Precision medicine in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32001655/)

[Chen R et al., GBA mutations in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31115465/)

[Simuni T et al., Parkinson's disease progression biomarkers (2020)](https://pubmed.ncbi.nlm.nih.gov/32209659/)

[Forker A et al., Biomarker development for neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33219876/)

External Links

[CU Anschutz](https://www.cuanschutz.edu)
[University of Colorado School of Medicine](https://medschool.cuanschutz.edu)
[CU Anschutz Research](https://research.cuanschutz.edu)
[Alzheimer's Disease Research Center](https://cuanschutz.edu/centers/alzheimers)
[Parkinson's Disease Research Center](https://medschool.cuanschutz.edu/pdrc)

📖 View canonical wiki page →

Related Entities

institutions-cu-anschutz-medical-campus

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-cu-anschutz-medical-campus
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1c47b7530af3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-cu-anschutz-medical-campus'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

20%

Debates

0

Incoming

4

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

cu-anschutz-medical-campus

University of Colorado Anschutz Medical Campus

Introduction

University of Colorado Anschutz Medical Campus

Introduction

Institutional History and Development

Origins in the University of Colorado School of Medicine

The Aurora Campus Transformation

Research Growth and Milestones

Research Programs and Centers

Alzheimer's Disease Research Center (ADRC)

Parkinson's Disease Research Center

Rocky Mountain MS Center

Center for ALS and Motor Neuron Disorders

Center for Neuroscience and Hulling Neuroscience Research

Key Research Focus Areas

Neuroinflammation Research

Protein Misfolding and Aggregation

Notable Researchers and Their Contributions

Leadership

Faculty

Research Facilities

Advanced Imaging Center

Clinical Trials Unit

Biorepository

Stem Cell Core

Behavioral Assessment Core

Training and Education

Graduate Programs

Medical Training

Postdoctoral Training

Clinical Research Training

International Collaborations

National Collaborations

International Partnerships

Therapeutic Development Pipeline

Alzheimer's Disease

Parkinson's Disease

ALS

Multiple Sclerosis

Precision Medicine Initiative

Components

Applications

Cross-Links to NeuroWiki Pages

Future Directions

Near-term Goals (2025-2027)

Long-term Vision (2027-2030)

Strategic Priorities

References

See Also

External Links

💬 Discussion